Thursday, the FDA pushed back its target action date by three months for Daiichi Sankyo’s investigational acute myeloid leukemia (AML) drug quizartinib, citing updates to the proposed Risk Evaluation and Mitigation Strategies (REMS).
Tag Archive for: target action dates
The U.S. Food and Drug Administration has a handful of PDUFA dates over the next two weeks.